Thus, before considering antidiabetic agents with weight-losing property (i.e., metformin, SGLT2i, GLP-1 RA, and tirzepatide) for their glycemic or cardiorenal benefits, we should assess the nutritional status and metabolic phenotype of the individuals and avoid using them in patients with malnutrition or malnutrition risk, at least until their nutritional status is optimized [48, 62]. The gene discussed is GCG; the disease is nutritional deficiency disease.